APL-501 (PD-1)

APL-501: Anti Programmed Death-1

Formerly CBT-501

APL-501 is a novel IgG4 humanized monoclonal antibody against the Programmed Death-1 (PD-1) membrane receptor on immune cells. It has a comparable efficacy profile in in vitro and in vivo studies to the marketed anti-PD-1 antibodies, nivolumab and pembrolizumab, and has a favorable profile with very low antibody-dependent cell-mediated cytotoxicity (ADCC) and complement dependent cytotoxicity (CDC) activity.

PD‑1 protein is expressed on immune cells called T cells normally acting as a type of "off switch" that helps keep the T cells from attacking other cells in the body (e.g. healthy cells). PD‑L1 protein is expressed on some normal cells and on cancer cells. PD-1 binds to PD‑L1 and this interaction signals T cells to leave the other cell alone and not attack it. This protects normal, healthy cells from immune attack. But, some cancer cells hijack PD‑L1 expression so the PD-1 expressing T cell adopts a “don’t attack” state which helps the cancer cells hide from the immune system and subsequently grow. Therapies that target PD-1 stop it from interacting with PD-L1. Similarly, therapies that target PD-L1 prevent PD-1 from interacting with it. This allows the T cell to attack cancer cells in the body and prevent them from hiding.

Apollomics retains worldwide rights to APL-501 outside of China.

Clinical Trials

APL-501 is currently being evaluated in several ongoing clinical trials. For additional information, please click on the trial links below.

Trial Details
Trial Name: APOLLO
Agents: APL-101 (c-Met inhibitor) + APL-501 (anti-PD-1)
Phase: Phase 1/2
Indication: Hepatocellular Carcinoma
Trial: NCT03655613
Trial Details
Type: Single Agent
Phase: Phase 1b
Indication: Solid Tumors
Trial: NCT03053466

China Partner & Clinical Trials:

Genor BioPharma Co. Ltd. has development rights in China for APL-501 where it is referred to as GB226.

Trial Details
Type: Single Agent
Phase: Phase 1
Indication: Peripheral T Cell Lymphoma
Trial: NCT03502629

Type:               Single Agent
Phase:             Phase 2
Indication:       B-cell Non-Hodgkin’s Lymphoma
Trial:               NCT03639181

Trial Details
Type: Single Agent
Phase: Phase 2
Indication: Alveolar Soft Part Sarcoma
Trial: NCT03623581
Trial Details
Type: Single Agent
Phase: Phase 1
Indication: Solid Tumors, Lymphoma
Trial: NCT03374007

Posters & Publications

Posters and Publications on our assets can be found here.